Article: Amsterdam Molecular Raises [euro]50M In IPO For Gene Therapies.

Staff Writer

The Dutch company Amsterdam Molecular Therapeutics Holding BV completed a C50 million (US$67 million) initial public offering to fund development of its gene-based therapies for orphan diseases.

Amsterdam-based AMT sold 5 million shares at C10 per share. ABN AMRO Rothschild and Kempen & Co. are underwriting the offering, and have an overallotment option to purchase up to 750,000 additional shares.

The shares, under the symbol "AMT," closed at C10.03 on the Euronext Exchange in Amsterdam in their debut Wednesday. The offering priced at the high range estimated when AMT filed its prospectus June 6. It said then it expected to sell up ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!